Volume 16, Number 10—October 2010
Research
Effectiveness of Personal Protective Equipment and Oseltamivir Prophylaxis during Avian Influenza A (H7N7) Epidemic, the Netherlands, 2003
Dennis E. te Beest
, Michiel van Boven, Marian E.H. Bos, Arjan Stegeman, and Marion P.G. Koopmans
, Michiel van Boven, Marian E.H. Bos, Arjan Stegeman, and Marion P.G. KoopmansTable 2
Risk for infection with avian influenza A (H7N7) with different levels of oseltamivir use, on the basis of combined conjunctivitis and serology-based case definition, the Netherlands, 2003*
| Oseltamivir use | Risk† (95% CI) |
|---|---|
| Not used | 0.145 (0.078–0.233) |
| Not prescribed | 0.161 (0.052–0.336) |
| Prescribed but not used during visit |
0.138 (0.061–0.246) |
| Used | 0.031 (0.008–0.073) |
| Prescribed and used consistently | 0.015 (0.0008–0.0630) |
| Prescribed and used inconsistently | 0.049 (0.004–0.157) |
| Prescribed and consistency of use unknown |
0.068 (0.004–0.258) |
| Unknown | 0.019 (0.001–0.080) |
| Prescribed but period of use unknown | 0.020 (0.001–0.080) |
*CI, confidence interval.
†Probability of infection per visit.
